Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555939 · ClinicalTrials.gov registry record · NA
Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
A NA study of Sickle Cell Disease, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06555939: Recruiting NA study of Sickle Cell Disease, sponsored by Boston Children's Hospital.
NCT06555939 is a NA study of Sickle Cell Disease that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 25 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06555939, a NA study of Sickle Cell Disease, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Adolescents and young adults with sickle cell disease (SCD) face challenges managing their illness and maintaining their well-being. This study proposes to test the feasibility and acceptability of a resilience-promoting intervention through a Collaborative Care Model. The primary goal is to determine with the resilience intervention (PRISM) is feasible and acceptable for adolescents and young adults with SCD. Exploratory outcomes include whether this intervention improves depression, anxiety, and pain interference.
Primary Outcome
feasibility assessed by \>50% enrollment rate
Conditions Studied
Interventions
- BEHAVIORAL Collaborative Care Model
- BEHAVIORAL Promoting Resilience in Stress Management
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2030-09 |
| Phase | NA |
What NCT06555939 shows while recruiting
NCT06555939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Collaborative Care Model is the first listed.
NCT06555939 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06555939 about?
NCT06555939 is a clinical study titled "Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease". Adolescents and young adults with sickle cell disease (SCD) face challenges managing their illness and maintaining their well-being. This study proposes to test the feasibility and acceptability of a resilience-promoting intervention through a Collaborative Care Model. The primary goal is to determi...
What is the current status of trial NCT06555939?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2025-10-23. Estimated completion is 2030-09.
What conditions does trial NCT06555939 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT06555939?
The interventions under investigation include: Collaborative Care Model (BEHAVIORAL), Promoting Resilience in Stress Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT06555939?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06555939 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06555939's enrollment target sits among peer trials
25 153rd of 213 higher than 55 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI